Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | FT836 |
| Trade Name | |
| Synonyms | FT 836|FT-836 |
| Drug Descriptions |
FT836 is an iPSC-derived CAR-T therapy that targets the alpha3 domain of MICA/B, which may lead to anti-tumor immune response (J Immunother Cancer 2024;12(suppl_2):Abstract 264). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cetuximab + FT836 | Cetuximab FT836 | 0 | 1 |
| Cetuximab + FT836 + Paclitaxel | Cetuximab FT836 Paclitaxel | 0 | 1 |
| Daratumumab + FT836 | Daratumumab FT836 | 0 | 1 |
| FT836 | FT836 | 0 | 1 |
| FT836 + Paclitaxel | FT836 Paclitaxel | 0 | 1 |
| FT836 + Paclitaxel + Trastuzumab | FT836 Paclitaxel Trastuzumab | 0 | 1 |
| FT836 + Trastuzumab | FT836 Trastuzumab | 0 | 1 |